摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-Chloro-3-(4'-fluorobiphenyl-4-yl)-7-hydroxy-chromen-4-one | 558642-37-8

中文名称
——
中文别名
——
英文名称
6-Chloro-3-(4'-fluorobiphenyl-4-yl)-7-hydroxy-chromen-4-one
英文别名
6-chloro-3-[4-(4-fluorophenyl)phenyl]-7-hydroxychromen-4-one
6-Chloro-3-(4'-fluorobiphenyl-4-yl)-7-hydroxy-chromen-4-one化学式
CAS
558642-37-8
化学式
C21H12ClFO3
mdl
——
分子量
366.776
InChiKey
GJOQSLAVOITVAD-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.2
  • 重原子数:
    26
  • 可旋转键数:
    2
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    46.5
  • 氢给体数:
    1
  • 氢受体数:
    4

反应信息

  • 作为反应物:
    描述:
    6-Chloro-3-(4'-fluorobiphenyl-4-yl)-7-hydroxy-chromen-4-one一水合肼 作用下, 以 乙醇 为溶剂, 生成 CCT072454
    参考文献:
    名称:
    The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors
    摘要:
    High-throughput screening identified the 3,4-diarylpyrazole CCT018159 as a novel and potent (7.1 mu M) inhibitor of Hsp90 ATPase activity. Here, we describe the synthesis of CCT018159 and a number of close analogues together with data on their biochemical properties. Some initial structure-activity relationships are discussed, as well as the crystal structure of CCT018159 bound to Hsp90. (c) 2005 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2005.05.046
  • 作为产物:
    参考文献:
    名称:
    The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors
    摘要:
    High-throughput screening identified the 3,4-diarylpyrazole CCT018159 as a novel and potent (7.1 mu M) inhibitor of Hsp90 ATPase activity. Here, we describe the synthesis of CCT018159 and a number of close analogues together with data on their biochemical properties. Some initial structure-activity relationships are discussed, as well as the crystal structure of CCT018159 bound to Hsp90. (c) 2005 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2005.05.046
  • 作为试剂:
    参考文献:
    名称:
    3,4-diarylpyrazoles and their use in the therapy of cancer
    摘要:
    本发明涉及使用公式(I)中的某些3,4-二芳基吡唑化合物,无论是在体内还是体外,用于抑制热休克蛋白90(HSP90),以及用于治疗由HSP90介导的疾病,包括癌症等;其中:Ar3独立地表示:C5-20芳基基团,可选地取代;Ar4独立地表示:C5-20芳基基团,可选地取代;R5独立地表示:氢;卤素;羟基;醚;甲酰基;酰基;羧基;酯,酰氧基;氧羰酰氧基;酰胺;酰胺基;氨基羰酰氧基;四唑基;氨基;硝基;氰基;偶氮基;磺酰基;硫醚基;磺酰胺基;C1-7烷基;C3-20杂环基;或C5-20芳基;R N 独立地表示:-H;C1-7烷基;C3-20杂环基;或C5-20芳基;以及其药学上可接受的盐,溶剂化合物,酰胺,酯,醚,化学保护形式和前药。本发明还涉及这种化合物,包含这种化合物的制药组合物,用于医学用途的这种化合物,用于治疗由HSP90介导的疾病,包括癌症的这种化合物,以及使用这种化合物制备这种治疗药物的用途。
    公开号:
    US20050222230A1
点击查看最新优质反应信息

文献信息

  • [EN] 3,4-DIARYLPYRAZOLES AND THEIR USE IN THE THERAPY OF CANCER<br/>[FR] 3,4-DIARYLPYRAZOLES ET LEUR UTILISATION EN THERAPIE ANTI-CNCEREUSE
    申请人:RIBOTARGETS LTD
    公开号:WO2003055860A1
    公开(公告)日:2003-07-10
    The present invention pertains to the use of certain 3,4-diarylpyrazoles of formula (I), both in vitro and in vivo, to inhibit heat shock protein 90 (HSP90), and in the treatment of conditions mediated by HSP90, including, for example, cancer; wherein: Ar3 is independently: a C5-20aryl group, and is optionally substituted; Ar4 is independently: a C5-20aryl group, and is optionally substituted; R5 is independently: hydrogen; halo; hydroxy; ether; formyl; acyl; carboxy; ester; acyloxy; oxycarbonyloxy; amido; acylamido; aminocarbonyloxy; tetrazolyl; amino; nitro; cyano; azido; sulfhydryl; thioether; sulfonamido; C1-7alkyl; C3-20heterocycyl; or C5-20aryl; RN is independently: -H; C1-7alkyl; C3-20heterocycyl; or, C5-20aryl; and pharmaceutically acceptable salts, solvates, amides, esters, ethers, chemically protected forms, and prodrugs thereof. The present invention also pertains to such compounds, pharmaceutical compositions comprising such compounds, such compounds for medical use, such compounds for use in the treatment of conditions mediated by HSP90, including, for example, cancer, and use of such compounds in the preparation of medicaments for such treatments.
    本发明涉及使用式(I)的特定3,4-二芳基吡唑化合物,无论是体外还是体内,以抑制热休克蛋白90(HSP90)的作用,并用于治疗由HSP90介导的疾病,例如癌症;其中:Ar3独立地表示:C5-20芳基基团,且可选地被取代;Ar4独立地表示:C5-20芳基基团,且可选地被取代;R5独立地表示:氢;卤素;羟基;醚;甲酰基;酰基;羧基;酯基;酰氧基;氧羰基氧基;酰胺基;酰胺氧基;氨基羰氧基;四唑基;氨基;硝基;氰基;偶氮基;硫醇基;硫醚基;磺酰胺基;C1-7烷基;C3-20杂环基;或C5-20芳基;RN独立地表示:-H;C1-7烷基;C3-20杂环基;或C5-20芳基;以及其药学上可接受的盐,溶剂化合物,酰胺,酯,醚,化学保护形式和前药。本发明还涉及这些化合物,包含这些化合物的制药组合物,用于医疗用途的这些化合物,用于治疗由HSP90介导的疾病,例如癌症的这些化合物,以及使用这些化合物制备此类治疗药物的用途。
  • 3,4-DIARYLPYRAZOLES AND THEIR USE IN THE THERAPY OF CANCER
    申请人:Vernalis (Oxford) Ltd
    公开号:EP1456180A1
    公开(公告)日:2004-09-15
  • 3-(2,4)DIHYDROXYPHENYL-4-PHENYLPYRAZOLES AND THEIR MEDICAL USE
    申请人:Vernalis (Cambridge) Limited
    公开号:EP1456180B1
    公开(公告)日:2007-10-03
  • US7247734B2
    申请人:——
    公开号:US7247734B2
    公开(公告)日:2007-07-24
  • The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors
    作者:Kwai-Ming J. Cheung、Thomas P. Matthews、Karen James、Martin G. Rowlands、Katherine J. Boxall、Swee Y. Sharp、Alison Maloney、S. Mark Roe、Chrisostomos Prodromou、Laurence H. Pearl、G. Wynne Aherne、Edward McDonald、Paul Workman
    DOI:10.1016/j.bmcl.2005.05.046
    日期:2005.7
    High-throughput screening identified the 3,4-diarylpyrazole CCT018159 as a novel and potent (7.1 mu M) inhibitor of Hsp90 ATPase activity. Here, we describe the synthesis of CCT018159 and a number of close analogues together with data on their biochemical properties. Some initial structure-activity relationships are discussed, as well as the crystal structure of CCT018159 bound to Hsp90. (c) 2005 Elsevier Ltd. All rights reserved.
查看更多